Wells Fargo lowered the firm’s price target on Integra LifeSciences to $45 from $49 and keeps an Overweight rating on the shares following quarterly results. The firm notes that there are “lots to digest again,” but was surprised by the magnitude of the stock move down. 2024 guide likely embeds some conservatism, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IART:
- Integra Lifesciences Announces CEO Transition and New Executive Chairman
- Integra LifeSciences CEO Jan De Witte to retire by the end of 2024
- Integra LifeSciences sees Q1 adjusted EPS 53c-57c, consensus 74c
- Integra LifeSciences sees FY24 adjusted EPS $3.15-$3.25, consensus $3.44
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
